News / Press
Press Inquiries
For further questions about any of our news items, or for additional resources on Entrigue Surgical, contact us at press@entriguesurgical.com.
RTI Biologics, ENTrigue Surgical announce development and supply
ALACHUA, Fla. (Dec. 15, 2008) — RTI Biologics, Inc. (RTI) (Nasdaq: RTIX), the Florida-based processor of orthopedic, dental, hernia and other biologic implants, announced today that it has signed an agreement to provide biologic implants to ENTrigue Surgical, Inc., the Texas-based manufacturer of medical devices and instrumentation for the surgical treatment of conditions of the ear, nose and throat (ENT).
Under the agreement, which is effective immediately, RTI Biologics will process soft tissue allograft and xenograft implants to help patients in ENT applications for distribution by ENTrigue. Long term, the two companies will co-develop novel biologic solutions for ENTrigue's surgeons and patients.
"We are pleased to offer biologic membrane tissues for ear, nose and throat applications through ENTrigue," said Brian K. Hutchison, RTI Biologic's chairman and chief executive officer. "We felt that ENTrigue was the right distributor for us in this market – ENTrigue's management team has well over 100 years of collective experience and success in the ENT surgical market and, like RTI, places an emphasis on innovative solutions for surgeons and patients. Working together, ENTrigue and RTI can bring biologic alternatives to patients while working to maximize each gift of donated tissue."
Fred Dinger, president and chief executive officer of ENTrigue Surgical commented, "Biological implants are emerging as a significant therapy platform in Otolaryngology, and RTI is at the forefront of innovation and safety in the field of biologics. We are very excited to embark on this partnership and foresee tremendous opportunity for developing unique biological solutions for ENT surgery."
About ENTrigue Surgical
ENTrigue Surgical is a privately held medical device company formed with the objective of innovating and delivering next generation devices and therapies for the ENT operating room and office. Products from ENTrigue Surgical focus on enhancing surgical access for increased functionality and precision. Unique to the industry, ENTrigue Surgical is also developing a new class of clinically proven bioabsorbable and biologic implants designed to simplify surgical procedures and improve healing. The company's website address is www.entriguesurgical.com.
About RTI Biologics Inc.
RTI Biologics, Inc. was formed when Regeneration Technologies, Inc. and Tutogen Medical, Inc. merged on Feb. 27, 2008. The company is now the leading provider of sterile biological implants for surgeries around the world with a commitment to advancing science, safety and innovation. RTI prepares human donated tissue and bovine tissue for transplantation through extensive testing and screening, precision shaping and proprietary, validated sterilization processes. These allograft and xenograft implants are used in orthopedic, dental, hernia and other specialty surgeries.
RTI's innovations continuously raise the bar of science and safety for biologics—from being the first company to offer precision-tooled bone implants and assembled technology to maximize each gift of donation, to inventing fully validated sterilization processes that include viral inactivation steps. Two such processes, the BioCleanse® Tissue Sterilization Process and the Tutoplast® process, sterilize tissue, are clinically successful and are scientifically proven to eliminate donor-to-recipient disease transmission risk while preserving tissue strength and biocompatibility. These processes have a proven record of more than two million implants distributed with zero incidence of infection. In addition, RTI pastes are sterilized through the demineralization process, a validated viral inactivation step.
